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ABCG2/ BCRP          breast cancer resistance protein 
AF   atrial flutter 
ATP   adenosintriphosphate 
AED   antiepileptic drugs 
ABC   ATP-binding cassette 
Da   Dalton 
ECG   electrocardiography 
GDM  gestational diabetes mellitus 
HIV  humanimunodeficiecyvirus 
MDR   multidrug resistance 
M-mode  motion-mode 
MRP   multidrug resistance-associated protein 
MXR   mitoxantrone resistance protein 
NBF   nucleotide-binding fold 
P-gp   P-glycoprotein 
PI   protease inhibitors 
OCT3   extraneuronal monoamine transporter 
hENT    human equilibrative  nucleoside transporters 
OCTN2  carnitine transporter 
SVT   supraventricular tachycerdia 
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For more than half a century, scientists and physicians have recognized pregnant 
women as a unique population from the point of view of drug therapy.  
Until the thalidomide-induced birth defects occurred in the early 1960s, 
physicians generally believed that the uterus provided a protective environment for the 
fetus.  
Subsequently, it has become accepted that any chemical substance, including 
any therapeutic agent, administered to a mother is able to permeate across the placental 
barrier and fetus(Yaffe, 1998).  
When managing a pregnant patient with medication, the treatment of mother and 
fetus, two individual patients, should be considered independently, and the decision 
must be based on the risk/benefit assessment of both (Gedeon and Koren, 2005). It must 
be evaluated in association with other treatment modalities like direct injection of drug 
to the fetal compartment or delivery, which is an option when the fetus is mature 
enough. 
Different clinical situations can occur with the demand for the treatment focused 
on mother or fetus, or the therapy of the same disease of both of them.  
The first group is represented by either chronic illnesses (diabetes mellitus, 
hypertension, asthma, epilepsy etc.) or newly arisen problems like gastrointestinal 
disturbances and infections of the mother. Although there is a continuing need to 
receive chronic medications during pregnancy, drug therapy is still often without a 
specific rationale (Yaffe, 1998).  
Modern pediatrics defined situations like fetal tachycardia, pulmonary 
immaturity which confer great morbidity and mortality numbers. These numbers 
support the preference of transplacental treatment over an expectance approach when 
clinicians wait to treat the disease state after delivery. 
The third group constitutes a drug administration to mother for the same purpose 
for both, mother and child. This is the case of HIV infection when the pharmacotherapy 
aims to  manage the active infection of mother and reduce the probability of vertical 
transmission to the child during labour. 
  For optimization of pharmacotherapy during pregnancy it is necessary to 
understand the mechanisms involved in the transported of drugs from mother to fetus 
across the placenta.  
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3. AIMS OF THE STUDY 
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 The aim of this work was to summarize recent information on the principles of 
transplacental passage of drugs and to review current approaches in the 
pharmacotherapeutic treatment of selected deseases in pregnancy in context with the 
transplacental drug transfer. The review is based on scientific information gained from 
the internet databases, such as Science Direct, Medline etc. 
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4.1.  Structure of placenta 
 
The primary function of all placentas is to act as an interface between the mother 
and fetus that allows appropriate metabolic exchanges of gases and selective transport 
of different molecules including nutrients and waste products. This function is 
accomplished by bringing maternal and fetal blood into close apposition while 
maintaining both separation of the two circulatory systems and the integrity of maternal 
and fetal organisms. 
Human placenta is a discoid organ formed by both fetal and maternal tissues. 
Maternal part gives rise to septa that mark out functional units – cotyledons. Each 
cotyledon comprises an arbour of villi, branching from large stem villi containing the 
major fetal vessels to free villi that extend into the intervillous space (containing 
maternal blood) (Kaufmann et al., 1988).  
The trophoblast and mesoderm overlying the intervillous space is called the 
chorionic plate. Those villi that spread along the maternal endometrium are called 
anchoring villi, and in the combination with the adjacent compact decidualized 
endometrium they form the basal plate. Maternal blood enters and leaves the 
intervillous space via the basal plate, whereas fetal vessels enter and leave the villi via 
the chorionic plate of the placenta.  
 
Fig. 2. A schematic representation of the human placenta. Modified from internet 
source: www.merck.com 
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Despite variation in the arrangement of layers, trophoblast always forms the 
external epithelium of the fetal component of the placenta. Trophoblast cells are found 
as large multinucleate cells layer, called syncytial trophoblast, which emerges by 
recruiting cytotrophoblast cells (Ringler and Strauss, 1990). The villi have a nearly 
complete cytotrophoblast layer underlying the surface layer of syncytial trophoblast 
during most of the first trimester, but as the gestation proceeds the cytotrophoblast cells 
become stelete and the layer discontinuous.  
Finally syncytial trophoblast develops thick and thin regions, with many of the 
thin regions closely apposed to fetal vessels, where the basement membrane is shared 
with the endothelial cells of the fetal capillary. Although the endothelium may be quite 
thin in these fetal vessels, it is continuous and does not contain fenestrations, so the role 
of the endothelium in the ‗barrier‘ should not be ignored (Firth and Leach, 1996). 
However, the rate-limiting barrier for permeation across the human placenta is the 
syncytiotrophoblast layer (Ala-Kokko et al., 1993; Sibley, 1994; Enders and 
Blankenship, 1999).  
 
Fig. 3. Schematic representation of the maternal-fetal interface in the placenta. 
ST - syncytiotrophoblast; CT - cytotrophoblast;  FV - fetal blood vessel. Adapted 
from Moe, 1995. 
 
Although the syncytial trophoblast appears to be continuous, it is sometimes 
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argued that the combination of basal bays and surface invaginations or a separate 
tubular system results in pathways through the syncytium (Kertschanska et al., 1997). 
Thus the layer of syncytiotrophoblast is histologically and functionally polarized 
with apical surface of maternal facing brush border membrane and fetal-facing basal 
membrane. 
Nomenclature of placental morphology is based on the contributions by different 
extraembryonic membranes and on the tissue layers intervening between maternal and 
fetal blood, separating them into three groups: hemochorial, endoteliochorial, 
epiteliochorial. Human placenta belongs to the group of hemochorial placentas, in 
which maternal blood directly bathes the trophoblast. These placentas can be referred to 
as being hemomono- (human), di- (rabbit), or trichorial (mouse, rat) depending on the 
number of layers of trophoblast cells present in the thinnest portions of the definitive 
placenta (Enders, 1965). For this reason, the information gained about the structure and 
function of placenta should be extrapolated from one species to another with caution 
(Finn, 1994). 
 
 
 
 
Fig. 4. Light micrograph of the villous hemomonochorial chorioallantoic placenta of the 
human. Fetal capillary (FC), maternal blood space (MBS). Adapted from Enders and 
Blankenship, 1999. 
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4.2.  Models for investigation of placental barrier 
 
A variety of in vitro systems currently exists to evaluate the transport and 
metabolism processes of many of the significant endothelial and epithelial tissue 
barriers to drug delivery. The emergence of in vitro models for the human placenta 
within past decades opened the door for investigations of drug transport and metabolism 
mechanisms and apply that knowledge to developing drugs that more selectively target 
either the mother or the fetus in drug therapy (Dancis and Liebes, 1995).  
Human trophoblast culture systems, both primary cultures and cell lines, also 
exist, including those that form monolayers, and have been used to study uptake and 
transport mechanisms at the cellular and molecular levels (Ringler and Strauss, 1990; 
Yui et al., 1994; Bloxam et al., 1997; Liu et al., 1997; Sastry, 1999).  
The obvious importance of the syncytial trophoblast in pregnancy and its ready 
availability from term placentas has resulted in extensive study of this tissue in 
relationship to maternal–fetal transfer (Sibley and Boyd, 1988; Smith et al., 1992). 
Modern cell biological methods have even permitted dissection of this layer by separate 
isolation of apical (microvillus) and basal cell membranes of syncytial trophoblast, as 
used in studies of glucose transporter protein (Jansson et al., 1993) and chloride 
transport (Powell et al., 1998).  
The single cotyledon model is used extensively to characterize the transport and 
the metabolism of numerous pharmacologic agents and nutrients. It is well established 
as a safe in vitro surrogate for human placental transfer. The major attribute that makes 
this a desirable model is that it demonstrates placental transport independent of fetal 
metabolism. Another advantage of this model is the ability to validate each experiment 
individually with the addition of antipyrine (Shenker et al., 1989; Shenker et al., 1987; 
Dancis et al., 1988). The ex vivo technique of dual perfusion of placental lobule (DPPL) 
has proved to be a powerful tool in the prediction of the extent of term placental transfer 
of drugs in vivo (Schneider et al., 1985). However, these data represent 1 time point in 
placental transfer of the drug, namely at delivery, and consequently do not reflect the 
dynamic changes in its concentration. 
One of the traditional in vitro model is BeWo cell line, originally derived from a human 
choriocarcinoma (Patillo and Gey, 1968), quite similar in morphological and 
biochemical features to normal trofoblast cells.  
In vivo techniques to study placental transfer of drugs involve animal studies for 
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measurement of maternal-fetal and fetal maternal clearance, thus studies with 
chronically catheterized macaque (Tuntland et al., 1998), baboon (Garland et al., 1998) 
and sheep (Kumar et al., 1999) have been developped to determine ther mechanism of 
placental drug transfer. 
Recently an imaging methodology providing a means of studying material 
transfers in the placenta at a much higher level of topographic and functional precision 
than previously possible was described. The use of an affinity-based tracer with a 
fluorescent tag, requiring a confocal scanning laser microscope, offers high detection 
sensitivity with high spatial and temporal resolution of processes within five 
compartments (maternal and fetal blood, syncytiotrophoblast, fetal endothelium, 
extracellular matrix). The methodology should set a new standard for studies of drug 
transfer to the fetus (Sölder et al., 2009). 
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4.3.   Drug transport across placenta 
 
Although the placenta was viewed as a protective barrier, the transmission to the 
fetus, of drugs administered to the mother is now widely demonstrated (Pacifici and 
Nottoli, 1995). With the exception of drugs with large molecular weights, such as 
heparin or insulin, most drugs appear to cross the placenta and are associated with 
varying degrees of fetal exposure. 
The predominant mechanism by which substances cross the human placental 
barrier is simple passive diffusion either transcellularly or paracellularly (Robinson et 
al., 1988; Ala-Kokko et al., 1993; Sibley, 1994) and depends upon the transmembrane 
concentration gradient. An inverse relationship generally exists between placental 
transport rates and molecular weight of substances that cross by passive diffusion 
(Schneider, 1991). The physicochemical properties of drugs play a significant role in 
determining transtrophoblast permeation. Molecules that are relatively lipophilic, with 
low protein binding, short elimination half-life, a low degree of ionization (pKa), and 
have molecular weights of less than 600 Da, permeate readily across the 
syncytiotrophoblast layer (Ala-Kokko et al., 1993).    
Several additional factors influence the overall placental permeation. These 
factors include the developmental changes in the placental barrier, such as pH and 
protein gradients, thickness and surface area of the barrier, volume of distribution, rate 
of metabolism and excretion by the placenta and placental blood flow, and specific 
placental transport systems (Elliott et al., 1991; Koren, 2001; Hardmons et al., 2006).  
The placenta expresses a number of carrier mechanisms that are well-characterized in 
other tissues and are yet of unknown physiological significance in placental function 
(Ganapathy et al., 1999). 
 
Other mechanisms including active transport and facilitated diffusion also 
operate in the placenta (Audus, 1999). Although most transporters at the placenta 
probably exist for the purpose of aiding transport of physiologically important 
substrates to the fetus, some transporters appear to prevent transport of chemicals 
(including toxins, xenobiotics) to the fetus (Unadkat et al., 2004).  
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            4.3.1.          Pharmacokinetic aspects 
 
Absorption phase can be altered by maternal changes in gastric secretion and 
motility, disturbing the degree of ionization and solubility. Once absorbed, maternal 
drug metabolism may be influenced due to elevation of endogenous hormones such as 
progesterone, which can stimulate the hepatic microsomal oxidase system and result in 
increased transformation of drugs such as phenytoin (Langer et al., 2000; Lobstein et 
al., 2001). Conversely, theophyline and caffeine experience reduced hepatic elimination 
as a consequence of elevated estradiol. 
Total body water expansion, including plasma volume (Bournissen et al., 2003) 
and generally increase in extracellular fluid space (Langer et al., 2000; Lobstein et al., 
2001) contributes to an increase in volume of distribution and may lower the 
concentration of drugs and increase their elimination half-life. 
Protein binding alterations may also occur as a result of changes in both the 
concentration of specific proteins and changes in protein binding affinity. Decrease in 
maternal serum albumin may lead to corresponding increase in the free fraction of drug 
(Beck, 1981; Boyd and Hamilton, 1970). Increased levels of free fatty acids and total 
lipids due to hormonal changes in pregnancy partially saturate the protein binding 
capacity for drugs. There is a markedly lower concentration of specific binding proteins 
and altered binding affinity of drugs in the fetus (Holcberg et al., 2003a) and there is a 3 
fold lower level of a1-acid glycoprotein in the fetus compared to the mother 
(Bournissen et al., 2003).   
Lipid solubility, the pH of the maternal and fetal fluids, the ionization constant 
of the drug (pKa) and the molecular weight also influence the passage of the drug across 
the placenta. In general, uncharged, un-ionized molecules with high lipid solubility and 
lower molecular weight penetrate the cell membranes more readily than hydrophilic 
ionized drug molecules (Heikkila et al., 1992). 
The pH gradient between the maternal and fetal circulations and the pKa of the 
drug also influence transfer of weak acids and bases. Since fetal plasma is 0.1 lower 
than maternal plasma pH, for weak bases the un-ionized free drug crossing the placenta 
becomes ionized and is trapped in the more acidic fetal circulation (Holcberg et al., 
2003a; Langer et al., 2000), resulting in fetal drug concentrations that may eventually 
exceed maternal plasma concentrations and lead to toxicity. The pH of the amniotic 
fluid is also lower than that of maternal plasma. 
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 4.3.2. ABC family transporters 
 
The ABC transporters are one of the largest families of active transport 
molecules (Higgins, 1992; Dean et al., 2001). There are 48 ABC genes in the human 
genome and they are dispersed mostly on different chromosomes, with a few clusters of 
2–5 genes (Dean et al., 2001).  
The structure of ABC transporters consists of two sets of hydrophobic segments 
that span the membrane and are thought to confer all or most of the specificity of the 
transporter, and a pair of ATP-binding domains or nucleotide-binding folds (NBFs). 
ABC genes either encode a full transporter encoding all four domains, or a half-
transporter with a single TM domain and a single NBF. Half-transporter proteins must 
dimerize as either homo- or heterodimers to form a complete transporter complex. All 
the transporters posses to a greater or leader extent extracellular N-glycosylation 
branches. Based on in vitro studies on P-gp (Shinkel et al., 1993) it appears that this N-
glycosylation is not necessary for the basic transport function of these transporters. 
However, N-glycosylation probably has an important cell-biological role for these 
proteins, helping in stabilizing membrane insertion and possibly routing to, and stability 
in the plasma membrane. 
The group of efflux transporters in the ABC superfamily have been identified in 
the placenta, where they are involved in detoxification processes and multidrug 
resistence, forming an essential part of the barrier (Young et al., 2003; Utoguchi et al., 
2000; Atkinson et al., 2003; Audus et al., 2002; Pascolo et al., 2003; Tanabe at al., 
2001; St-Pierre et al., 2000; Ushigome et al., 2003). 
The generally accepted mechanism of multidrug resistance is that the efflux 
transporters expel a variety of structurally diverse drugs, drug conjugates and 
metabolites from cells against considerable concentration gradients in an ATP-
dependent manner, usually from the apical membrane surface of polarized epithelial 
cells (Bodo et al., 2003). These efflux transporters include P-glycoprotein (P-gp), which 
is encoded by the MDR1 gene, multidrug resistance-associated proteins (MRP-
1through-6 and 10-12), and breast cancer-resistance protein (ABCG2) (Ozben, 2006). 
Other ABC transporters have been implicated in drug resistance, but these other 
transporters play highly specialized roles in normal physiology and are less likely to be 
usurped to play a role in drug resistance. 
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4.3.2.1.  P – glycoprotein 
 
Juliano and Ling in 1976 were the first to note that a particular 170 kD 
glycoprotein was associated with this resistance (Juliano and Ling, 1976) and over a 
decade later the gene encoding P-gp, then termed mdr1 (and later called MDR-1), was 
cloned (Roninson et al., 1986). P-glycoprotein polypeptide consists of two very similar 
halves, each containing 6 putative transmembrane segments, and an intracellular ATP 
binding site, with the first extracellular loop being N-glycosylated.  
P-gp is mainly present in epithelial cells of adrenals, kidneys (brush border cells 
of proximal tubules), liver (biliary canalicular surface of hepatocytes), colon (apical 
surface of columnar epithelial cells), small intestine (epithelial cells), brain (capillary 
endothelial cells), peripheral nerves (capillary endothelial cells), heart, placenta and 
testes (Fojo et al., 1987; Thiebaut et al., 1987; Saito et al., 1997), where it localizes to 
the apical membrane (Thiebaut et al., 1987; Higgins, 1992).  
In the human placenta there is abundant expression of the MDR1 gene 
throughout pregnancy (Mylona et al., 1996; Allikmets et al., 1998) with significant 
levels of P-gp, demonstrated by immunohistochemistry (MacFarland et al., 1994). 
Studies with human microvillar membranes of term human trophoblasts have indicated 
an active MDR1 (Nakamura et al., 1997).  Although P-gp is found in the placentas of 
gravid mice and tends to increase during pregnancy (Novotna et al., 2004), Gil et al. 
(2005) showed a significant decrease of its level in human placenta from the 13-14th to 
the 38-41st week of gestation, suggesting that the ability of the placenta to protect the 
fetus from xenobiotics is greater in early pregnancy than at term. The possibility that 
different cell types within the placenta express P-gp at different stages of gestation 
really exists (Gil et al., 2005).  
It confers a chemoresistance to cells for numerous xenobiotics by actively 
pumping molecules outside cells, in fact translocating its substrates from the basolateral 
to the apical side of the epithelium and consequently decreasing their intracellular 
concentrations (Kartner et al., 1983). This ability to extrude xenobiotics gives this 
protein some physiological properties of protection and detoxification. This principle 
has been directly demonstrated using P-gp deficient mutant or knockout mice for at 
least four different P-gp substrates: an analogue of the pesticide avermectin, the cardiac 
glycoside digoxin, the HIV protease inhibitor saquinavir, and the anticancer drug 
paclitaxel (Lankas et al.,1998; Sugawara et al., 1988; Huisman et al., 2001). However, 
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P-gp is also implicated in the transport and regulation of endogenous molecules such as 
hormones (Wolf and Horwitz, 1992; Ueda et al., 1992) or phospholipids (Oude Elferink 
et al., 1996; Pohl et al., 2002).  
P-gp is involved in the pharmacokinetics of numerous drugs, participated in the 
absorption, distribution and elimination phases, on contrary to cytochrome P450 
enzymes that are only involved in drug metabolism.  
Different types of P-gp interaction exist. First a direct interaction with the 
binding sites on P-gp blocking transport of substrates (e.g. verapamil, cyclosporin A) in 
competitive or non-competitive manner, and secondly an inhibition of ATP binding 
(e.g. vanadate), ATP hydrolysis (e.g. cyclosporin A) or coupling of ATP hydrolysis to 
the translocation of the substrate (Ambudkar et al., 1999). But the mechanisms of P-gp 
inhibition are rather complicated and depend on both substrates and inhibitors, and do 
not always follow simple kinetics (Lin, 2003). Thus it can be supposed that compounds 
able to interact with P-gp activity could induce important modifications of 
bioavailability for numerous concomitantly administered drugs.  
         The transplacental transfer of several drugs such as saquinavir, paclitaxel, and 
digoxin in P-gp knockout mice has been shown to be 2–16 times greater as compared 
with mice with functional P-gp (Smith et al., 1999). Therefore, one might propose that 
the use of drugs that are P-gp substrates would reduce fetal drug exposure (Lankas et 
al., 1998).  Their most striking property is the diversity with few common structural 
denominators. They are usually organic molecules ranging in size from less than 200 Da 
to almost 1900. Most of the efficiently transported molecules are uncharged or (weakly) 
basic in nature, but some acidit compounds can also be transported, albeit at a low rate. 
As most P-gp substrates are quite hydrophobic, in principle they can diffuse passively 
across biological membranes at a reasonable rate.  
In the case of desirable increase of penetration of P-gp substrates beyond 
placental barrier, as with the therapy of fetus, inhibition of P-gp would allow substrates 
of P-gp to cross in considerable amount. Studies evaluating human placental transfer of 
P-gP substrates such as saquinavir have demonstrated that inhibition of P-gp can 
markedly impair its protective efflux function (Mölsä et al., 2005). Thus the uptake of 
P-gp substrates drugs into the fetus can be increased by P-gp inhibitors such as 
cyclosporin A, verapamil and progesterone (Ushigome et al., 2000). 
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Tab. 1. Selected clinically significant substrates of P-gp. Adapted from (Čečková-
Novotná et al., 2006). 
Cytotoxic drugs: 
vinca akaloids, taxanes, antracyclines, actinomycin D, epipodophyllotoxins 
HIV protease inhibitors: 
amprenavir, saquinavir, ritonavir, nelfinavir, indinavir 
Antibiotics: 
erythromycin, levofloxacin, gramicidin B 
Cardiac drugs: 
digoxin, quinidine, carvedilol, celiprolol, talinolol 
Antiemetics: 
domperidone, ondasetrone 
Others: 
ivermectine, colchicine, losartan, phenytoin, morphine 
 
 
However, different results have been found in perfused human placenta, in 
which neither quinidine nor verapamil were able to enhance digoxin concentration in 
the foetal compartment (Holcberg et al., 2003b). The main hypothesis was related by 
authors to the placenta‘s age. Effectively, progesterone is a potent inhibitor of P-gp 
activity and its levels increase with pregnancy age. Thus P-gp activity is probably 
strongly down-modulated in mature placentas, explaining the lack of inhibitor effect.  
The interaction between quinidine and digoxin is directly linked to P-gp 
inhibition, confirmed by the fact that in knock out mice (mdr1a-/-), digoxin plasma 
levels are not modified by quinidine, whereas in wild-type mice, quinidine significantly 
increases plasma digoxin levels by 73% (Fromm et al., 1999).  
In the case of proton pump inhibitors, which are known to interact with drug 
metabolising enzymes, a recent in vitro study has clearly demonstrated that omeprazole, 
lansoprazole and pantoprazole are are able to down-modulate digoxin efflux (Pauli-
Magnus et al., 2001).  
 Many of the initially identifies inhibitors, like the calcium channel blocker 
verapamil or the immunosupressive agent cyclosporin A, turned out to be themselves 
transported substrates of P-gp, suggesting that they act as competitive inhibitors. For 
other inhibitors no significant transport by P-gp could be demonstrated, indicating that 
they probably work through other mechanisms. Still, it may be that some of the latter 
compounds are just diffusing so quickly across membranes that transport by P-gp, 
although it does occur, is not detectable (Litman et al., 2001). 
Actually, the P-gp inhibitors that were initially recognized, such as verapamil, 
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are actually relatively poor P-gp inhibitors in vivo, because of their own 
pharmacodynamic effects that severely restrict the plasma levels that can be achieved. 
By now there are many P-gp inhibitors with increasingly suitable properties for clinical 
use. 
 
Tab. 2.  P-gp inhibitors. Adapted from Čečková-Novotná et al., 2006. 
First generation chemosensitizers: 
verapamil, quinidine, cyclosporin A, progesterone, tamoxifen, trifluoperazine 
trifluopromazine, flupentixol 
Second generation chemosensitizers: 
dexverapamil, PSC833, biricodar, GF120918, MS-209 
Third generation chemosensitizers: 
LY335979, OC144093, XR9576 
Herbal extracts: 
St.John‘s, Rosemary, Rhei Rhizoma, Ephedrae herba 
Antibodies: 
MRK16 
 
 
Food can also interact with P-gp. For example, grapefruit juice, a well-known 
enzymatic inhibitor of cytochrome P450 that leads to increased bioavailability of co-
administered drugs, is implicated in interactions with P-gp, although with rather 
contradictory results. Three studies made evident an inhibition of P-gp activity by 
grapefruit juice on P-gp expressing cell cultures, that increased vinblastine and talinolol 
cell levels (Wang et al., 2001; Takanaga et al., 1998; Spahn-Langguth and Langguth, 
2001). But studies in humus failed to prove an significant effect of grapefruit juice on 
human P-gp activity (Becquemont et al., 2001). Piperine, a major component of black 
pepper, is also known to down-modulate efflux activity of P-gp and inhibit digoxin and 
cyclosporin A transport in P-gp overexpressing cells (Bhardwaj et al., 2002).  
 
4.3.2.2.    MRPs 
 
Multidrug resistance-associated proteins (MRPs) constitute another member 
family of ABC transporters. Currently there are nine known MRPs, six of them fully 
sequenced. Recent findings show that human placenta at term expresses at least free 
members of MRP family: MRP 1, MRP 2 and MRP 3. MRP 2 is expressed on the apical 
membrane of syncitiotrophoblast, while MRP 1 and MRP 3 are expressed on the 
basolateral membrane and the blood vessel endothelia (Borst et al., 2000). 
 25 
Their size and function vary greatly. In contrast P-gp, MRPs appeal to efflux 
polar compounds (Borst et al., 2000) and function mainly as a (co-)tranporter of 
amphipathic organic anions. It can transport hydrophobic drugs and other compounds 
(for example inflammatory mediator leukotriene C4), as proved Mrp1 knockout mouse 
who were viable and fertile but showed deficiencies in LTC4-mediated inflammatory 
reactions (Robbiani et al., 2000), that are conjugated or complexed to glutathione, to 
glucuronic acid, or to sulfate (Leier et al., 1994; Müller et al., 1994; Evers et al., 1996; 
Loe et al., 1996).  
The role of MRPs in the placenta has not been fully explained, but it is likely to 
bear (besides possible pharmacological role) important physiological activity. For more 
detalied review of numerous members of this group please see the review article 
(Schinkel and Jonker, 2003).  
 
4.3.2.3.   ABCG2 
 
The most recently discovered ABC drug efflux transporter is BCRP, named for 
breast cancer resistance protein since it was cloned from a breast cancer subline, or 
mitoxantrone resistance protein, since it appeared to be responsible for the high levels 
of resistance to mitoxantrone observed in cell lines expressing the gene (Dietel et al., 
1990; Nakagawa et al., 1992). Later it was placed in the ―G‖ subfamily of ABC 
transporters and called ABCG2. Unlike the discussed transporters, this is a half-
transporter, like the whole ―G‖ subfamily, consisting of only a single N-terminal, 
intracellular ATP binding site, followed by 6 putative transmembrane segments. The 
last extracellular loop is in all likelihood N-glycosylated (Maliepaard et al., 2001a). 
ABCG2 is a 72-kDa protein composed of 665 amino acids. The transmembrane 
domain of ABCG2 (residues 361 to 655) is predicted to have six transmembrane 
segments and an extracellular loop between segments five and six. Since ABCG2 is a 
half-transporter, it is believed to homodimerize, or possibly oligomerize in order to 
function (Ozvegy et al., 2001), in contrast to other members of the G subfamily of 
transporters ABCG5 and ABCG8, which heterodimerize to form a functional 
transporter (Graf et al., 2002). A tetrameric structure made up of four homodimer 
complexes was suggested (McDevitt et al., 2006). Building a phylogenetic tree using 
protein sequences of primates suggests that the function of ABCG2 has remained 
relatively conserved across vertebrate evolution (Robey et al., 2009).  
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By northern blot analysis, high levels of ABCG2 expression in placenta were 
reported (Doyle et al., 1998), specifically in the syncytiotrophoblasts as examined by 
immunohistochemistry (Maliepaard et al., 2001a). ABCG2 is believed to protect the 
developing fetus from the possible transmission of toxins as well as remove toxins from 
the fetal space (Jonker et al., 2000), as demonstrated for example in studies of transport 
of cimetidine from the fetal to maternal space against a concentration gradient (Staud et 
al., 2006),  ABCG2 mediated transfer of 14C-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine (Myllynen et al., 2008) and fetal penetration of glyburide (Pollex et al., 2008; 
Zhou et al., 2008; Gedeon et al., 2006; Gedeon et al., 2008). 
The list of substrates and inhibitors of ABCG2 has been steadily expanding 
since its discovery, but yet no clear structure–function relationship has been identified 
that would explain the definitive requirements for a substrate or for an inhibitor. It is 
hoped that closer insights into the structure of ABCG2 could translate into a better 
understanding of the function of the protein, yielding potent and specific inhibitors 
(Robey et al., 2009). 
 
Tab. 3. Selected non-chemotherapy substrates of ABCG2. Adapted from Robey et al., 
2009. 
Antivirals: 
zidovudine (AZT), lamivudine, abacavir 
HMG-CoA reductase inhibitors: 
rosuvastatin, pitavastatin, cerivastatin 
Antibiotics: 
ciprofloxacin, ofloxacin, norfloxacin, erythromycin, 
nitrofurantoin 
Calcium channel blockers: 
Azidopine, dipyridamole, nitrendipene 
Other compounds: 
sulfasalazine, cimetidine, riboflavin, vitamin K3, glyburide, 
d-Luciferin 
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4.3.3. Other transporters 
 
Transporters that are facilitative (or equilibrative) can function both as influx or 
efflux transporters depending on directionality of the concentration gradient (Unadkat et 
al., 2004). It comprises groups of extraneuronal monoamine transporter (OCT3), human 
equilibrative  nucleoside transporters 1 and 2 (hENT1 and hENT2), carnitine transporter 
(OCTN2) 
Extraneuronal Monoamine Transporter (OCT3) is a Na
+
 and Cl
-
-independent 
monoamine transporter and belongs to the family of organic cation transporters. This 
transporter is responsible for importing dopamine and norepinephrine into the fetal 
compartment, and is sensitive to inhibition by steroids. The physiological substrates of 
OCT3 include serotonin, dopamine, norepinephrine and histamine, OCT3 also interacts 
with the antidepressant desipramine (Shang et al., 2003). Transport defects in Orct3-
deficient mice have been observed in embryonic development, indicating the importace 
of OCT3 function during pregnancy (Zwart et al., 2001). 
Although hENT1 is throught to be situated on the brush-border membrane of the 
placental syncytiotrophoblasts (Barros et al., 1995), the placental localization of hENT2 
is currently unknown. hENT1 and hENT2 have a broad specificity for nucleosides and 
nukleoside drugs, both transport purine and pirimidine nucleosides but with different 
affinities (Ward et al., 2000). hENT1 transports cytidine, guanosine, thymidine and 
adenosine with a higher affinity, while hENT2 transports inosine with a higher affinity 
than hENT1. The two transporters also differ significantly in their sensitivity to 
inhibition by the inosine analog, nitrobenzylthioinosine (NBMPR) (Ward et al., 2000; 
Yao et al., 2002; Griffith and Jarvis, 1996). hENT1 and hENT2 efficiently transport 
drugs (Lum et al., 2000) such as gemcitabine (Mackey et al., 1998) and ribavirin (Jarvis 
et al., 1998).  
Carnitine Transporter (OCTN2) is localized at the placental brush-border 
membrane (Wu et al., 2000) as well as in the blood-brain barrier (Friedrich et al., 2003), 
OCTN2 transports carnitine into these privileged sites. The transport of cations by 
OCTN2 occurs in a Na
+
-independent manner, whereas the transport of zwitterions 
occurs in a Na
+
-dependent manner (Wu et al., 2000).  
Because OCTN2 transports organic cations, its activity can be inhibited by 
cationic drug substrates. Ohashi et al. (1999) showed that many zwitterionic and 
cationic drugs inhibit OCTN2 in human embryonic kidney cells, including 
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tetraethylammonium, pyrilamine, quinidine, verapamil and valproate.  
 
4.3.4. Placental metabolism 
 
Apart of the active efflux transporters placenta itself can serve as a metabolic 
shield, as it is known to express a wide range of enzymes involved in phase I as well as 
in phase II of biotransformation reactions (Pasanen, 1999) possibly reducing fetal 
exposure.  
In the case of CYP enzymes, there has been confirmed functional activity in the 
placenta for isoforms CYP1A and CYP2E1. The CYP1A1/1A2 isoform is the dominant 
CYP variant present in the placenta and is inducible by exposures to xenobiotics 
including polycyclic aromatic hydrocarbons, components of tobacco smoke.  Additional 
isoforms, CYP19 (aromatase) and CYP11B (cholesterol side chain-cleaving enzyme) 
are also known to be present in the placenta throughout pregnancy. Placenta has the 
potential to express other CYP isoforms depending on the length of gestation and the 
health of the mother (Pasanen, 1999). 
Activity of several phase II enzymes (e.g. sulphotransferases, glutathione-S-
transferases, uridine diphosphate glucuronosyltransferases or N-acetyltransferase) was 
also revealed in placental tissue. However, none of these enzymes has been proven to 
play an important role in detoxication of xenobiotics (Pasanen, 1999; Syme et al., 
2004). Therefore, proper placental metabolism of drugs and xenobiotics seems to be of 
relatively minor importance in limiting drug passage across the placenta (Syme et al., 
2004). 
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5. PHARMACOTHERAPY OF DISEASES IN 
PREGNANCY 
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There is a strong evidence for many conditions that the immediate management 
during gestation decreases morbidity and mortality rates. In many cases results advise to 
prefer transplacental drug treatment over other modalities and encourage clinicians to 
treat mother and her child during pregnancy. Maternal DM, treatment of HIV infected 
pregnant women in order to prevent vertical transmission of the virus and fetal 
tachycardia belong to the most challenging situations. 
 
5.1.  Diabetes mellitus 
 
Gestational diabetes mellitus affects 3-10% of pregnancies, and the incidence 
continues to rise with the rising rates of obesity. Approximately 50% of the women 
require medication. The intervention demonstrated a 67% lower risk for a serious 
perinatal outcome (Crowther et al., 2005). 
 Insulin is the preferred pharmacological treatment in pregnancy because it is 
unable to cross the placenta due to its large molecular weight (6000 Da), but pain, 
discomfort as well as the increased cost and training required to administer injections 
make compliance with the therapy a critical issue. 
Oral hypoglycemic agents exemplify a group of medications that has been 
excluded from use in obstetrics for many years, mostly because of the little information 
about their transplacental passage available. Metaanalysis failed to show increased 
teratogenic risk among women treated with oral hypoglycemic agents (OHAs) during 
the first trimester (Gutzin et al, 2003). 
 
 
5.1.1.  Glyburide 
 
Several studies that compared insulin with glyburide, a second-generation 
sulfonylurea, demonstrated similar efficacy in achieving glycemic control (Langer et al., 
2000; Fines et al., 2003; Jacobson et al., 2005; Langer et al., 2005; Ogunyemi et al., 
2007). Neonatal outcomes after glyburide are similar to insulin (Langer et al., 2000; 
Fines et al., 2003), so it appears to be safe by measures of obstetric and neonatal 
outcomes (Moretti et al., 2008), or by an evalution of neonatal body composition which 
precisely reflects individual effects of the maternal environment on fetal growth and 
better estimates fetal effects of various methods of maternal glycemic control (Lain, 
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2009).  
The use of glyburide during pregnancy has potential advantages including 
decreased 
cost, ease of administration, fewer side effects, and patient satisfaction.  
Glyburide has been shown to exhibit marginal placental transfer (Robidoux et al, 
1998). A randomized control trial (Langer et al., 2000) found no detectable levels of 
glibenclamide in cord serum. Glibenclamide‘s exceptionally high protein binding, 
above 99.8%, allows for less than 0.2% of free drug to circulate and cross the placenta. 
Additionally, its high protein binding is coupled to a short elimination half-life made 
possible by its low volume of distribution (0.2 l/kg) and rapid clearance (1.3 
ml/kg/min). In short, glibenclamide has only a brief opportunity to cross the placenta 
(Feig et al., 2004; Koren, 2001). 
Elliott et al.‘s (1991) dually perfused human placental model showed virtually 
no appearance of glibenclamide in the fetal circulation. Even when maternal 
concentrations were 8 fold greater than therapeutic peak levels, suggesting 
glibenclamide may be actively pumped back to maternal circulation, and can both 
maintain maternal steady state concentrations and normoglycemia while decreasing 
fetal exposure and risk of hypoglycemia. 
Recent research, using the ex vivo human placental perfusion model, has 
revealed that glyburide is effluxed by an active mechanism against a concentration 
gradient from the fetal to the maternal compartment and that this mechanism is not 
affected by the P-glycoprotein inhibitor verapamil (Kraemer et al, 2006).  
Further investigation carried out on P-gp, MRP1-3 and ABCG2 overexpressing 
cell lines indicated that glyburide is preferentially transported by ABCG2 and MRP3 
(Gedeon et al, 2006). Additional research using placental brush border membrane 
vesicles revealed a significant increase in the vesicular uptake of glyburide in the 
presence of novobiocin, a  ABCG2 inhibitor, while MRP3 inhibition did not 
demonstrate a similar effect (Gedeon et al, 2008). Hence, this study provides the first 
evidence for ABCG2 as the specific transporter responsible for the active efflux of 
glyburide in the human placenta.  
In addition, the possible involvement of other placental transporters, such as 
MRP5, remains to be established (Meyer Zu Schwabedissen et al, 2005). Likely the 
involvement of MRP transporters in the transport of glyburide, if any, is not clinically 
significant.  
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The data on the kinetics of the formation of glyburide metabolites by the 
microsomal preparations from human and baboon livers and placentas strongly suggest 
that several cytochrome P450 isozymes are involved (Zharikova et al., 2007).However, 
the activity of placental enzymes changes with gestation (Hakkola et al., 1998) and its 
metabolism of glyburide cannot be determined at the different preterm gestational ages.  
Moreover, the metabolites formed in the presence of human placental and 
hepatic microsomes were identical. The major metabolite formed by human placenta is 
M5 (ethyl-hydroxy glyburide), which contributes 87% of the total (Zharikova et al., 
2007). But it is not clear whether they pharmacologically active and what are their 
effects on peri- and neonatal outcome. 
It can be concluded that the CYP isozymes metabolizing glyburide in human 
placenta might be similar to those in the liver, and the lower activity is due to decreased 
expression (Hakkola et al., 1998).  
As mentioned above we can consider glibenclamide and insulin equally effective 
in achieving good glycemic control and in the influence on perinatal outcomes, so the 
published data is robust enough to recommend glibenclamide to GDM women who are 
reluctant to accept insulin. 
 
 
5.1.2.  Metformin 
 
Recently, metformin, currently the only used biguanide, was compared with 
insulin treatment in gestational diabetes mellitus (GDM) patients, and found to be 
similarly as effective as insulin for maternal blood glucose control and neonatal 
outcome (Moor et al, 2005).  
Only scarce data exist explaining the mechanism by which metformin crosses 
biological membranes (Wang et al, 2003; Kimura et al, 2005a; Kimura et al, 2005b) and 
the exact mechanism of the transplacental transfer of metformin is unknown. 
Metformin is a weak base, highly polar, positively charged hydrophilic 
compound, with a small molecular weight, a low binding capacity to plasma proteins, 
and is not known to freely diffuse through cell membranes. The exact mechanism by 
which metformin crosses the biological membranes is not completely understood. 
Metformin has been shown to act as a substrate for three organic cation transporters 
OCT1, OCT2, and OCT3, which are the only transporters known to be involved in 
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metformin transport to date. There are no current data indicating the presence of OCT1 
presence in human placenta, OCT2 is only moderately expressed and OCT3 has 
considerable expression in human placental tissue (Unadkat et al., 2004). Therefore, it 
can be speculated that OCT3, and to some extent OCT2, are responsible for the 
transport of metformin across the human placenta.  
Additional studies are needed to assess the exact mechanism of metformin 
transport across the human placenta, and possible accumulation in the fetal 
compartment.  
The risk to the fetus could be either direct (ie, dependent on the amount of the 
drug transferred from the maternal to fetal circulation) or indirect (ie, because of the 
effects of the 
drug on placental functions).  
The transfer and distribution of metformin in placentas that were obtained from 
uncomplicated pregnancies was not different from diabetic placentas and indicates that 
GDM does not affect the transfer or distribution of metformin, no accumulation of the 
drug in the placental tissue occured. Metformin does not affect placental glucose uptake 
or transport (Elliot et al., 1997). 
Based on the results of ex vivo metformin transfer model (Kovo et al., 2008), it 
could be assumed that fetal exposure to this medication is low, suggesting the safety of 
its use during pregnancy. However, this assumption contradicts recently published data 
that reveals that metformin concentrations in both umbilical artery and vein are roughly 
the same as in maternal serum (Vanky et al, 2005). In the same report (Vanky et al., 
2005), the concentration of metformin in the umbilical vein exceeded that in the 
maternal serum, and the authors suggested that the fetus can excrete metformin to the 
amniotic fluid and reabsorb it into the fetal circulation by swallowing. 
Metformin transferred to the fetal circulation will remain as a free/active drug 
because of its lack of binding to plasma and tissue proteins. Because metformin is a 
hydrophilic drug, the increased total body water volume during pregnancy and 
enhanced renal elimination could reduce its concentration in maternal plasma and 
require dose adjustment. 
We can conclude that metformin is able to cross the mature human placenta, 
thus, fetal exposure must be considered when treating pregnant women with metformin. 
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5.1.3.   Rosiglitazone 
 
Rosiglitazone is a member of thiazolidinediones, potent oral antihyperglycemic 
agents (Patel et al., 1998; Cox et al., 2000) that reduces insulin resistence (Matthews et 
al., 1999) exerting its glucose-lowering effect by binding to peroxisome proliferator-
activated receptor γ (Lehmann et al., 1995; Berger et al.,, 1996). Rosiglitazone improves 
sensitivity to insulin in muscle and adipose tissues and inhibited hepatic 
gluconeogenesis.  
Both glyburide (Elliott et al., 1994) and rosiglitazone (Cox et al., 2000) have 
similar molecular weights and cross placenta by simple diffusion. In addition, 
rosiglitazone is similar to glyburide in that it is extensively (99.8%) bound to plasma 
proteins, particularly albumin. This property of rosiglitazone may explain why the drug 
did not cross into the fetal circulation. Clearance indices of rosiglitazone in the placental 
perfusion studies now reported are comparable with those previously reported for 
glyburide (Elliott et al., 1991; Elliott et al., 1994; Koren, 2001). 
Rosiglitazone, like other drugs of this class, contains a thiazolidinedione core but 
differs from pioglitazone, englitazone, and troglitazone in the presence of an 
aminopyridyl side chain (Perry and Petrie, 1998; Young et al., 1998). It is believed that 
these side chain substitutions are responsible for differences in disposition, metabolism, 
and antidiabetic efficacy (Berger et al., 1996).  
Rosiglitazone has fewer side effects than other thiazolidinediones, importantly 
though, rosiglitazone has been associated with less hypoglycemia and decreased C-
peptide, insulin, and proinsulin levels when compared with glyburide.  
  Rosiglitazone has been classified as a pregnancy category C drug. No ill effects 
on implantation or teratogenicity have been observed in animal studies, however, the 
use of rosiglitazone in rat and rabbit models has been associated with fetal growth 
restriction.  
Although demonstrated, there is also negligible transfer of rosiglitazone across 
the placenta with minimal fetal accumulation, further human studies are needed with 
regard to the safety and efficacy of rosiglitazone before it can be considered for the 
management of pregnancies complicated by diabetes. 
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5.2.  HIV infection 
 
About 6000 HIV-infected women were delivered of live-born infants in 1989 in 
USA (Oxtoby, 1990). With an infection rate of about 30%, about 1800 children were 
HIV-infected.  
About 90% of HIV-infected children is due to vertical transmission from the 
infected mother. This perinatal transmission of HIV occurs as a result of transplacental 
dissemination of the virus and intrapartum exposure to infected blood and genital tract 
(Duff, 1996; Bryson, 1996; John and Kreiss, 1996). 
As HIV crosses the placenta and infects the fetus (Connor et al., 1994; Sperling 
et al., 1996), the treatment of pregnant women with antivirals has two purposes: to 
protect the mother against HIV and to avoid vertical transmission of this virus. HIV 
therapy usually consists of nucleosidic analogue inhibitors of reverse transcriptase in 
combination with one HIV protease inhibitor.  
 
 
5.2.1.    Reverse transcriptase inhibitors 
 
In vitro and in vivo results are consistent with the view that the nucleoside 
reverse transcriptase inhibitors cross the human placenta and produce significant 
pharmacological concentrations in the fetal circulation. Nevirapine, the only studied 
non-nucleoside reverse transcriptase inhibitor, reach the equilibrium between the fetal 
and maternal concentration.  
The nucleoside reverse transcriptase inhibitors, and probably the non-nucleoside 
reverse transcriptase inhibitors, but more information is necessary for these latter drugs, 
cross the human placenta and reach pharmacological significant concentrations in the 
fetal blood. 
           With the exception of didanosine, the nucleoside reverse transcriptase 
inhibitors and nelfinavir, a non-nucleoside reverse transcriptase inhibitor, cross the 
placenta and the cord, and maternal plasma concentrations equilibrate (Pacifici, 2005). 
Cord blood concentrations of zidovudine and lamivudine tend to equal maternal 
concentrations at the time of delivery, whereas cord blood concentrations of didanosine 
and zalcitabine are approximately 50% that of maternal concentrations (Rogers et al., 
1990; Sanberg and Slikker, 1995). Non-nucleotide reverse transcriptase inhibitors, such 
as nevirapine, have also been shown to cross the placenta (Mirochnick, 2000; Rogers et 
al., 1990). Several factors may account for their passage including the drug‘s lower 
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protein binding (60%), low molecular weights, favorable degree of lipophilicity (Voit et 
al., 1985). As well, the majority are not P-gp substrates. Hence, these drugs passively 
diffuse across the placenta and are administered in sufficient doses to cross the placenta 
and prevent maternal-fetal transmission of HIV during labor (Gedeon and Koren, 2006). 
According to the data by Bawdon et al. (1992), didanosine has the lowest 
clearance index (0.13) among the nucleoside reverse transcriptase inhibitors and the 
cord to maternal plasma ratio is lower than the unity (Pons et al., 1991; Chappuy et al., 
2004b). Among the nucleoside reverse transcriptase inhibitors, abacavir has the highest 
clearance index (0.47) and the cord and maternal plasma concentrations of this drug 
equilibrate (Chappuy et al., 2004b). The second and third clearance index is that of 
zidovudine (0.28—0.54) and lamivudine (0.25), and the concentrations of these drugs 
equilibrate in the cord and maternal blood. The highest clearance index was obtained 
with bisheteroypiperazine (0.75), a non-nucleoside reverse transcriptase inhibitor, and 
this antiviral should cross the placenta well but little is known about this drug (Pacifici, 
2005). 
 
            5.2.2.     Protease inhibitors 
 
Both the results obtained in vitro and in vivo show that the protease inhibitors 
poorly transfer the placenta because of their great molecular weight. When the 
molecular weight is greater than 500Da, the clearance index is lower than 0.1 and the in 
vivo placental transfer is incomplete as it is in the case for ritonavir and saquinavir. The 
molecular weight of these compounds ranges from 506Da (amprenavir) to 721Da 
(ritonavir) (Pacifici, 2005). 
The transfer rates of the protease inhibitors ritonavir and saquinavir have been 
extremely low (Casey and Bawdon, 1998; Forestier et al., 2001). Chappuy et al. (2004a) 
have recently shown that the protease inhibitors have a poor transfer across the human 
placenta. 
A recent in vivo study also suggested low placental transfer of both drugs 
(Marzolini et al., 2002). Both saquinavir and ritonavir are known P-gp substrates and a 
possible reason for low transfer is P-gp mediated efflux (Pacifici and Nottoli, 1995). 
Protease inhibitors are substrates of P-gp and few human data are available to evaluate 
their effect in utero (Lee at al., 1998). 
 
Protease inhibitors (PI) do not cross the placenta to a clinically appreciable 
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extent (Maarten et al., 2001). Nelfinavir, ritonavir, saquinavir and lopinavir undergo 
incomplete transplacental transfer (Owen et al., 2005). Low PI placental transfer can be 
attributed to high protein binding (98%) and that these drugs are substrates for placental 
P-gP transporter (Huisman et al., 2000). For example, Saquinavir is a P-gP substrate 
with a high molecular weight (767 g/mol), high protein binding (98%) and partition 
coefficient which may contribute to the small amount that crosses the placenta 
(Forestier et al., 2001). 
 
The protease inhibitors reduce the mother‘s viral load but cannot be used to 
protect the fetus against HIV (Pacifici, 2005). 
However, if certain protease inhibitors are effluxed by the placenta, and do not 
reach the fetus, future use of the appropriate ABC inhibitor may allow for greater 
concentrations in the fetal compartment and the prevention of materno-fetal HIV 
transmission (Gedeon and Koren, 2006). 
             
 
            5.2.3.     Fusion inhibitors 
 
Enfuvirtide, is the first member of a novel class of antiretroviral agents, the 
fusion inhibitors, which interfere with the entry of HIV-1 into the human immune cell 
(Williams, 2003).  
It seems not to be transferred across the placental barrier. Even at maternal 
concentrations twice above therapeutic levels, no placental transfer of enfuvirtide was 
observed (Ceccaldi et al., 2008).  
The high molecular weight of the molecule (4492 kDa) and its ionized state may 
account for the lack of placental transfer (Gavard et al., 2006; Ghosn et al., 2004). First, 
it is unlikely to lead to any toxicity to the fetus, suggesting that enfuvirtide could be 
used in HIV-infected pregnant women without causing fetal exposure, on the other 
hand, it would not have any benefit as direct in utero postexposure prophylaxis to 
protect the fetus from vertical HIV transmission (Ceccaldi et al., 2008). 
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5.3.  Fetal tachycardia 
 
Fetal tachycardia, defined as a heart rate greater than 180 beats/min regardless of 
gestational age, is a condition that occurs in approximately 0.4% to 0.6% of all 
pregnancies (Bergmans et al., 1985). The subset of these cases with more sustained 
periods of tachycardia and higher heart rates is associated with congestive heart failure, 
fetal hydrops, neurologic morbidity, and intrauterine death (Naheed et al., 1996; 
Sonesson et al., 1996; Donn and Bowerman, 1993). Most centers have therefore opted 
for prenatal intervention in the form of maternal pharmacologic treatment (Allan et al., 
1991; Kleinman et al., 1985; Simpson and Sharland, 1998; Cuneo and Strasburger, 
2000; Van Engelen et al., 1994; Frohn-Mulder et al., 1995; Jaeggi et al., 1998; Sonesson 
et al., 1998; Ebenroth et al., 2001; Krapp et al., 2002; Strasburger, 2000; Oudijk et al., 
2000; Oudijk et al., 2002).  
Sustained tachycardias are indications for therapy because of their potential to 
produce fetal hydrops, which is characterized by masive anasarca, cardiomegaly, 
hepatosplenomegaly, and polyhydramnios. The mortality reaches as high as 50% to 
98% (Iliff et al., 1983; Kleinman et al., 1982; Etches and Lemons, 1979; Hutchison et 
al., 1982). 
In the case of persistent tachycardia, established by M-mode fetal 
echocardiography, it is strongly recommended to initiate transplacental treatment, as it 
can improve prognosis dramatically (Pézard et al., 2008). Before initiation of therapy, 
preexisting maternal arrhythmias and/or a prolonged QT segment should be excluded by 
a thorough examination of medical history and a maternal ECG (Oudijk et al., 2004).  
 
After 20 years of accumulated experience, the therapeutic protocol consists of 
the use of four main agents and a three-stage strategy. 
Digoxin is administered as first choice, and if it fails it is followed by flecainide 
(Allan et al., 1991; Frohn-Mulder et al., 1995) or sotalol (Oudijk et al., 2000) either on 
their own or with digoxin as second-line therapy. In this scheme, amiodarone remains 
on reserve for refractory cases and is only used as a third-line agent (Strasburger , 
2005). 
 
5.3.1.   Digoxin 
 
The cardiac glycoside digoxin is clinically used to treat fetal tachyarrhythmias 
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and fetal congestive heart failure (Holcberg et al., 2003b). Digoxin is the most 
commonly used drug (Ito et al., 1994). A steady-state serum digoxin concentration is 
low in pregnancy, compared to nongravid state (Rogers et al., 1972). Pharmacokinetics 
of digoxin during pregnancy is characterized by increased clearance and shorter 
elimination half-life (Azancot-Benisty et al., 1992). Therefore, a dose to maintain 
therapeutic concentrations of digoxin tends to be higher during pregnancy than usual. 
There are no specific data on pharmacokinetics of the other drugs in pregnancy (Ito, 
2001). 
Digoxin has been the drug of first choice in many centers, it is a well-known 
drug with a good evidence-based in neonates and children (Pézard et al., 2008). The 
presence of hydrops is associated with a lower success rate of digoxin monotherapy 
(Van Engelen et al., 1994). This is ascribed to poor placental diffusion of digoxin in 
hydropic placenta (Younis and Granat, 1987).  
Clinically significant interactions between digoxin and P-glycoprotein inhibitors 
have been well recognized.  
Verapamil increases digoxin serum concentrations by inhibiting P-glycoprotein-
mediated digoxin excretion. Similarly in the treatment of fetal tachyarrhythmia, 
coadministered verapamil may enhance digoxin transfer into fetus by blocking placental 
P-glycoprotein. 
Pharmacological manipulation of placental P-glycoprotein and/or other 
transporters has become a potential new option to optimize pharmacotherapy for fetal 
tachyarrhythmias (Ito, 2001).  
 
In conclusion, digoxin is a safe drug in the treatment of fetal tachycardia, 
however, its use results in relatively low conversion rates, and frequently second line 
drugs are required to achieve sinus rhythm (Oudijk et al., 2004).  
 
 
5.3.2.   Flecainide 
 
It has been proposed as an effective drug in the treatment of SVT, especially 
SVT associated with hydrops, either as drug of first choice or in combination with 
digoxin. The transplacental transfer is good (Wagner et al., 1990; Bourget et al., 1994; 
Barjot et al., 1998). 
It has been used as drug of second choice in nonhydropic SVT, and drug of 
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first choice in hydropic SVT resulting in conversion rates ranging from 75 – 92 % 
(Allan et al., 1991; Ebenroth et al., 2001; Krapp et al., 2002). 
Its use in fetal tachycardia therefore is mainly concentrated on SVT complicated 
by hydrops. It has been associated with intra-uterine deaths, however, the occurrence of 
an intrauterine death is a well known complication in fetal hydrops, and we can only 
speculate on the exact relationship with flecainide (Oudijk et al., 2004). 
 
 
5.3.3.    Sotalol 
 
The placental transfer is excellent (Oudijk et al., 2003), as sotalol passes the 
placenta easily and completly (O´Hare et al., 1980). Apparently sotalol does not 
accumulate in the fetus, which implies that the excretion of sotalol by the fetal kidney is 
efficient close to term. The adequate renal excretion may explain the relatively high 
concentration of sotalol in amniotic fluid. Statistically a strong relationship between the 
maternal blood level and the success of therapy was not shown. The therapy-resistant 
cases required either electrical cardioversion or multiple drug therapy, which suggests 
that the success of therapy may be more related to the type of arrhythmia (Oudijk et al., 
2003).  
Sotalol seems to be more efficacious than other drugs in fetal AF. The success 
rate of sotalol as a single therapy in the treatment of atrial flutter in the reported studies 
was approximately 65 %, and reached 80 % after the addition of digoxin (Oudijk, 
2003). 
 Sotalol has been associated with intrauterine deaths, mainly in hydropic cases 
with SVT (Oudijk et al., 2000), we opted for a different strategy (Oudijk et al., 2002). 
The success rate in fetal SVT was approximately 55 % with sotalol as a single drug and 
reached 75 % after the addition of digoxin (Oudijk et al., 2004). 
As proarrhythmia effect of sotalol is known to be dose-related (Hohnloser and 
Woosley, 1994), low initiation doses are preferable and dosage increases should be 
stepwise.  
Some beta-blockers, such as propranolol, have been associated with intrauterine 
growth retardation (Pruyn at al., 1979), but sotalol is not associated with fetal growth 
restriction (Oudijk et al., 2003). 
 
In conclusion, sotalol is a very potent drug in the treatment of fetal AF, with or 
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without hydrops, and is recommended as drug of first choice. Sotalol seems 
contraindicated in SVT complicated by hydrops (Oudijk et al., 2004). 
 
 
5.3.4.    Amiodarone 
 
The transplacental transfer is relatively low (Oudijk et al., 2003). Recently, a 
large study by Strasburger et al. (2004) was published in which amiodarone was 
initiated in drug-refractory fetal tachycardia complicated by hydrops. A high success 
rate of 93 % in SVT was accomplished, and a lower conversion rate of 33 % in AF 
(Strasburger et al., 2004). 
Traditioinally, amiodarone was used as third-line therapy and reserved for 
refractory cases, although amiodarone was shown to be effective for all fetuses, whether 
they were hydropic or not, and whether the agent was used alone or in association with 
digoxin, with the exception of two cases. It confirms observations made by Kositeth et 
al. (Khositseth et al., 2003), Jouannic et al. (2003) and Strasburger et al. (2004). 
Amiodarone is equally so after maternal oral administration (even in hydropic 
cases), with a relatively rapid onset of action despite its mediocre transplacental passage 
(Pézard et al., 2008). Maternal tolerance to amiodarone was also good. No maternal 
thyroid complications were observed. Two patients given the amiodarone-digoxin 
combination showed elevated levels of serum digoxin and clinical signs of digitalis 
intolerance. Amiodarone is known to raise the plasma levels of digoxin, which therefore 
necessitates careful dosage adjustments (Marcus, 1983). Fetal cardiac tolerance was 
also acceptable. To our knowledge, pulmonary and ocular complications linked to the 
use of amiodarone in fetuses have not been reported. Nevertheless, we must attempt to 
keep the duration of amiodarone administration during fetal life as short as possible 
(Pézard et al., 2008). 
 
In conclusion, amiodarone is efficient in the treatment of fetal tachycardias after 
oral maternal administration. When amiodarone is used as first-line monotherapy in 
hydropic fetuses, its benefits seem to outweigh the risks, both for the fetus and mother. 
The study also suggests that amiodarone may be a valuable first-line choice for the 
treatment of less severe forms of fetal STV (Pézard et al., 2008). 
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6. CONCLUSION 
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The expanding knowledge concerning transplacental drug transfer was enabled 
by the development of models in vivo and ex vivo. The layer of syncytiotrophoblast was 
shown as a rate-limiting for drug permeation and pharmacokinetic studies revealed that 
substance penetration is greatly influenced by the activity of efflux transporters. Their 
interactions with inhibiting substances and their own substrates can modulate 
transplacental distribution. 
Detailed investigation of interactions of these substances can offer a framework 
for sophisticated therapy with minimized fetal exposure, or on the contrary, learn to 
give preference to the passage of drugs towards the fetus and target it as the object of 
therapy. 
According to current level of knowledge, appropriate drug candidates, which 
respond by their physical-chemical features to be optimal gestational medications (for 
example glyburide), have been designated. But continued research and sorting 
information will help to achieve more safety for both mother and child. 
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7. SUMMARY 
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After thalidomide-induced birth defects affair, the view of uterus as 
pharmacologically unconquerable site dramatically changed. Subsequently it was 
accepted that any chemical substance permeates across the placenta. As there was a 
continuing need for many mothers to continue to receive medications for chronic 
disease states, extensive research was launched to gain an appropriate rationale.  
Progressive investigation of placental barrier compounds allowed the emergence 
of in vitro and in vivo models, which enabled particularly drug transport studies. 
Syncytiotrophoblast plays an important role as a rate-limiting component of the barrier.  
Detailed understanding of pharmacokinetic changes that occur during gestation 
offered a rationale for pharmacotherapy in pregnancy (large charged molecule, 
excessive protein-binding, short elimination half-life, volume of distribution, fetal-
maternal serum pH gradient). The mechanism of passive diffusion is most important 
way of drug transport.  
Perfusion studies clarified the crucial role of active efflux transporters, members 
of ABC protein family, namely P-glycoprotein, multidrug resistence-associated proteins 
a ABCG2. As P-gp was first to be discovered, is the most studied until now. Its 
substrates and inhibitors are well defined and their interactions are cardinal for rational 
pharmacotherapy in pregnancy. Although, many metabolizing enzymes have been 
identified within placental tissue, including CYP450 isoforms, they seem not to be a 
limiting factor in transplacental passage of drugs. 
Pharmacotherapy can be targeted to mother, fetus or both as in the case HIV 
infection. 
Similar efficacy and safety in the treatment of GDM was proved for insulin and 
oral hypoglycemic agents. The molecule of glyburide was shown as a prototype of an 
optimal agent for the therapy of mother. 
There are marked differences in two concomitantly administered groupes of anti 
HIV drugs: reverse transcriptase inhibitors readily cross the placenta and efficiently 
suppress the activity of virus within the fetus, while protease inhibitors in fact don´t 
penetrate and their effect is restricted to the maternal compartment, where they decrease 
the viral load.  
The most used and successful drugs in fetal tachycardia are digoxin, sotalol, 
flecainide and amiodarone, which are indicated according to the natural of arrythmia 
and clinical status (presence of fetal hydrops). 
Further exploration of efflux transporters modulation will contribute to safer and 
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much more effective treatment. 
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8. SOUHRN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
Po thalidomidové aféře se náhled na farmakologickou nedostupnost placenty 
významně změnil. Následně byl přijat názor, že placentu prostupuje v podstatě 
jakákoliv chemická látka. Jelikož je potřeba léčit chronické choroby matky i během 
těhotenství, strhla se vlna výzkumů, která měla dát této léčbě racionální podklad. 
Postupné získávání informací o jednotlivých složkách placentární bariéry 
umožnilo vznik in vitro a in vivo modelů, které podpořily studium léčiv. 
Syncytiotrofoblast hraje důležitou roli v rychlosti přestupu léčiv přes bariéru. 
Pro distribuci léčiv je nezbytné uvažovat změny ve farmakokinetice během 
těhotenství (vazba na bílkoviny, distribuční objem, krátký eliminační poločas, 
polarizace, pH gradient mezi sérem matky a plodu). Pro většinu léčiv je nejdůležitějším 
mechanismem transportu pasivní difuze.  
Klíčovou roli v definitivním prostupu do fetálního kompartmentu má skupina 
ABC proteinů, v placentě zastoupena především P-glykoproteinem, skupinou MRP 
transportních proteinů a ABCG2 transportérem. P-gp byl objeven jako první a je nejlépe 
prozkoumán. Bylo definováno mnoho jeho substrátů a inhibitorů, jejichž vzájemné 
interakce jsou stěžejní pro racionální farmakoterapie v těhotenství. I když byla v rámci 
vlastní placentární tkáně definována celá řada enzymů (včetně izoforem CYP450), zdá 
se, že nejsou limitujícím faktorem pro transplacentární přestup léčiv. 
Cílem farmakoterapie může být jak primárně matka nebo plod, tak v případě 
HIV infekce oba.  
V terapii gestačního diabetu mellitu byla prokázána srovnatelná účinnost a 
bezpečnost insulinu i perorálních antidiabetik. Na modelu glyburidu byl definován 
prototyp léku s optimálními vlastnostmi pro terapii matky.  
Mezi základními skupinami společně podávaných látek v terapii HIV infekce 
jsou významné rozdíly: inhibitory reverzní transkriptázy snadno prostupují a působí na 
virus i v rámci plodu, zatímco inhibitory proteázy v podstatě neprostupují a jejich 
účinek je omezen na organismus matky, tudíž na snížení virové nálože. 
Nejužívanější a nejúspěšnější léčiva používaná v léčbě fetální tachykardie jsou 
digoxin, sotalol, flekainid a amiodaron. Jsou indikovány dle podstaty arytmie a 
klinického stavu (přítomnost fetálního hydropsu). 
Další výzkum modulace funkce lékových transportérů přispěje k bezpečnější a 
efektivnější léčbě.    
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